Efficacy and Safety of LYR-210 for the Treatment of Chronic Rhinosinusitis in Adults

Summary

Multicenter, phase III, randomized, blinded, controlled, parallel group with safety extension phase with crossover or continued treatment.

Timeline

Start

2022-01-27

Primary completion

2024-03-04

Completion

2024-09-16

Outcome

Missed primary endpoint

release “ENLIGHTEN 1 did not meet its primary endpoint of demonstrating statistically significant improvement compared to sham control” lyratherapeutics.com ↗

Drugs

Indications